Kim BS, et al. - Researchers conducted the study for analyzing the impacts of ruxolitinib (RUX), a potent, selective inhibitor of JAK1 and JAK2, cream on itch and quality of life (QoL) in atopic dermatitis (AD), a chronic, highly pruritic skin disorder. In total, 307 adult patients with an Investigator's Global Assessment (score of 2 or 3) and 3% to 20% affected body surface area have been randomly assigned for 8 weeks to receive double-blind treatment with RUX (1.5% twice daily, 1.5% once daily, 0.5% once daily, or 0.15% once daily), vehicle twice daily, or triamcinolone cream (0.1% twice daily for 4 weeks then vehicle for 4 weeks). With all RUX cream regimens, a clinically relevant and prompt decrease in itch and significant increases in QoL were observed compared with vehicles. Rapid and persistent itch alleviation was noted with 1.5% RUX cream twice daily, which corresponded to decreased QoL burden.